[
  {
    "id": 1,
    "repeat_id": 1,
    "question": "What prognostic factors were analyzed in relation to disease-free survival and overall survival in node-positive patients?",
    "answer": "\nThe study analyzed several prognostic factors in node-positive patients, including the number of positive lymph nodes, HER-2/neu amplification (measured by copy numbers), log(PGR), tumor size, log(ER), and age. These factors were evaluated using univariate and multivariate analyses to determine their impact on disease-free survival (relapse) and overall survival. HER-2/neu amplification refers to the presence of extra copies of the HER-2 gene in cancer cells, which can influence tumor behavior. Higher HER-2/neu levels were linked to worse outcomes, as shown by survival curves. Tumor size and node count were also strongly associated with both relapse and overall survival.",
    "ground_truth": "The excerpt indicates that the prognostic factors analyzed include the number of positive nodes and HER-2/neu status. Specifically, the paper states: 'number of positive nodes 0. 0001 0. 0002' and 'her - 2 / neu 0. 0011 < 0. 0001'. This demonstrates that both factors are statistically significant in predicting survival outcomes.",
    "source": "'number of positive nodes 0. 0001 0. 0002 her - 2 / neu 0. 0011 < 0. 0001'",
    "difficulty": "hard",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:57:23",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 29.27849054336548
  },
  {
    "id": 1,
    "repeat_id": 2,
    "question": "What prognostic factors were analyzed in relation to disease-free survival and overall survival in node-positive patients?",
    "answer": "\nThe study analyzed the following prognostic factors in node-positive patients: **number of positive lymph nodes**, **HER-2/neu amplification** (measured by copy numbers in cancer cells), **log(PGR)** (progesterone receptor levels), **tumor size**, **log(ER)** (estrogen receptor levels), and **age**. These factors were evaluated using both **univariate** and **multivariate analyses** to assess their independent associations with **disease-free survival** (relapse) and **overall survival**. HER-2/neu amplification, in particular, showed significant impacts on outcomes, with higher copy numbers correlating with poorer prognosis. Tumor size and lymph node involvement were consistently linked to both survival endpoints. The analysis also incorporated Cox\u2019s proportional hazards model to account for interactions among variables.",
    "ground_truth": "The excerpt indicates that the prognostic factors analyzed include the number of positive nodes and HER-2/neu status. Specifically, the paper states: 'number of positive nodes 0. 0001 0. 0002' and 'her - 2 / neu 0. 0011 < 0. 0001'. This demonstrates that both factors are statistically significant in predicting survival outcomes.",
    "source": "'number of positive nodes 0. 0001 0. 0002 her - 2 / neu 0. 0011 < 0. 0001'",
    "difficulty": "hard",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:57:32",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 8.618971347808838
  },
  {
    "id": 1,
    "repeat_id": 3,
    "question": "What prognostic factors were analyzed in relation to disease-free survival and overall survival in node-positive patients?",
    "answer": "\nThe study analyzed **number of positive lymph nodes**, **HER-2/neu amplification** (measured by copy numbers in cancer cells), **log(PGR)** (progesterone receptor levels), **tumor size**, **log(ER)** (estrogen receptor levels), and **age** in node-positive patients. These factors were evaluated using **univariate** and **multivariate analyses** to determine their associations with **disease-free survival** (relapse) and **overall survival**. HER-2/neu amplification, tumor size, and lymph node count were most strongly linked to outcomes, while ER and PGR levels showed moderate associations. Age also contributed to survival predictions in multivariate models.",
    "ground_truth": "The excerpt indicates that the prognostic factors analyzed include the number of positive nodes and HER-2/neu status. Specifically, the paper states: 'number of positive nodes 0. 0001 0. 0002' and 'her - 2 / neu 0. 0011 < 0. 0001'. This demonstrates that both factors are statistically significant in predicting survival outcomes.",
    "source": "'number of positive nodes 0. 0001 0. 0002 her - 2 / neu 0. 0011 < 0. 0001'",
    "difficulty": "hard",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:57:41",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 9.518523216247559
  },
  {
    "id": 2,
    "repeat_id": 1,
    "question": "What potential therapeutic implications are suggested by the identification of the ligand in breast cancer?",
    "answer": "\nThe identification of HER-2/neu as a ligand in breast cancer suggests **targeted therapeutic strategies** for patients with HER-2 overexpression. This biomarker helps identify patients who may benefit from **HER-2-directed therapies**, such as monoclonal antibodies (e.g., trastuzumab) or tyrosine kinase inhibitors, which block HER-2 signaling and inhibit tumor growth. Such targeted treatments have significantly improved outcomes for HER-2-positive breast cancers, underscoring the importance of **biomarker-driven personalized therapy** in oncology.",
    "ground_truth": "The identification of its ligand and the development of specific antagonists could have important therapeutic implications. Specifically, the paper states: 'identification of its ligand and development of specific antagonists could have important therapeutic implications.' This demonstrates that targeting the ligand may lead to new treatment strategies for breast cancer.",
    "source": "identification of its ligand and development of specific antagonists could have important therapeutic implications.",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 13:57:50",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 8.440544366836548
  },
  {
    "id": 2,
    "repeat_id": 2,
    "question": "What potential therapeutic implications are suggested by the identification of the ligand in breast cancer?",
    "answer": "\nThe identification of the HER-2/neu ligand in breast cancer highlights its role as a **critical therapeutic target**. Patients with HER-2 overexpression (as indicated by amplification) are now routinely treated with **HER-2-targeted therapies** (e.g., trastuzumab, pertuzumab, ado-trastuzumab emtansine), which have significantly improved survival rates compared to traditional chemotherapy alone. This underscores the importance of **biomarker-driven personalized treatment** and has led to the development of **precision oncology approaches**. Additionally, HER-2 status guides **adjuvant therapy decisions** and helps predict response to neoadjuvant treatments, emphasizing its clinical relevance in stratifying patients for optimal care.",
    "ground_truth": "The identification of its ligand and the development of specific antagonists could have important therapeutic implications. Specifically, the paper states: 'identification of its ligand and development of specific antagonists could have important therapeutic implications.' This demonstrates that targeting the ligand may lead to new treatment strategies for breast cancer.",
    "source": "identification of its ligand and development of specific antagonists could have important therapeutic implications.",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 13:57:58",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 8.092192888259888
  },
  {
    "id": 2,
    "repeat_id": 3,
    "question": "What potential therapeutic implications are suggested by the identification of the ligand in breast cancer?",
    "answer": "\nThe identification of the HER-2/neu ligand in breast cancer highlights its role as a **critical therapeutic target**. Patients with HER-2 overexpression (as indicated by amplification) are now routinely treated with **HER-2-targeted therapies** (e.g., trastuzum, pertuzumab, ado-trastuzumab emtansine), which have significantly improved survival rates compared to traditional chemotherapy alone. This underscores the importance of **biomarker-driven personalized treatment** and has led to the development of **precision oncology approaches**. Additionally, HER-2 status guides **adjuvant therapy decisions** and helps predict response to neoadjuvant treatments, emphasizing its clinical relevance in stratifying patients for optimal care.",
    "ground_truth": "The identification of its ligand and the development of specific antagonists could have important therapeutic implications. Specifically, the paper states: 'identification of its ligand and development of specific antagonists could have important therapeutic implications.' This demonstrates that targeting the ligand may lead to new treatment strategies for breast cancer.",
    "source": "identification of its ligand and development of specific antagonists could have important therapeutic implications.",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 13:58:04",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 6.128984212875366
  },
  {
    "id": 3,
    "repeat_id": 1,
    "question": "What is the significance of the her-2/neu oncogene in human breast cancer as discussed in the excerpt?",
    "answer": "\nThe **HER-2/neu oncogene** is significant in human breast cancer as it is strongly associated with **aggressive tumor behavior** and **poorer prognosis**, particularly in node-positive patients. Its amplification (overexpression) correlates with **reduced disease-free survival** and **overall survival**, as shown in the study's analysis of actuarial survival curves. This makes HER-2/neu a critical **prognostic biomarker** for risk stratification. Additionally, its identification has driven the development of **targeted therapies** (e.g., trastuzumab), transforming treatment paradigms for HER-2-positive breast cancers and improving outcomes through **precision oncology**.",
    "ground_truth": "The her-2/neu oncogene is significant in human breast cancer as it has been shown to be amplified in breast cancer cell lines. Specifically, the paper states: 'this gene has been shown to be amplified in human breast cancer cell lines.' This demonstrates that amplification of this oncogene may correlate with disease progression.",
    "source": "'this gene has been shown to be amplified in human breast cancer cell lines.'",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:58:12",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 7.561457395553589
  },
  {
    "id": 3,
    "repeat_id": 2,
    "question": "What is the significance of the her-2/neu oncogene in human breast cancer as discussed in the excerpt?",
    "answer": "\nThe **HER-2/neu oncogene** is significant in human breast cancer as it is a **key prognostic marker** and **therapeutic target**. In the study, its **amplification (overexpression)** was strongly linked to **poorer disease-free and overall survival** in node-positive patients, as evidenced by actuarial survival curves. This highlights its role in identifying high-risk subgroups requiring aggressive treatment. Additionally, the oncogene's significance extends to **precision oncology**, as its targeting has enabled the development of life-saving therapies like **trastuzumab**, revolutionizing outcomes for HER-2-positive breast cancers.",
    "ground_truth": "The her-2/neu oncogene is significant in human breast cancer as it has been shown to be amplified in breast cancer cell lines. Specifically, the paper states: 'this gene has been shown to be amplified in human breast cancer cell lines.' This demonstrates that amplification of this oncogene may correlate with disease progression.",
    "source": "'this gene has been shown to be amplified in human breast cancer cell lines.'",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:58:18",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 5.8382346630096436
  },
  {
    "id": 3,
    "repeat_id": 3,
    "question": "What is the significance of the her-2/neu oncogene in human breast cancer as discussed in the excerpt?",
    "answer": "\nThe **HER-2/neu oncogene** is significant in human breast cancer as it serves as a **prognostic marker** and **therapeutic target**. The study emphasizes that its **amplification** (overexpression) is strongly associated with **poorer survival outcomes** in node-positive patients, as demonstrated by actuarial survival curves. This underscores its role in identifying high-risk subgroups. Furthermore, its significance lies in driving the development of **targeted therapies** (e.g., trastuzumab), which have transformed treatment strategies and improved outcomes for HER-2-positive breast cancers.",
    "ground_truth": "The her-2/neu oncogene is significant in human breast cancer as it has been shown to be amplified in breast cancer cell lines. Specifically, the paper states: 'this gene has been shown to be amplified in human breast cancer cell lines.' This demonstrates that amplification of this oncogene may correlate with disease progression.",
    "source": "'this gene has been shown to be amplified in human breast cancer cell lines.'",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:58:24",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 6.6416120529174805
  },
  {
    "id": 4,
    "repeat_id": 1,
    "question": "What method was used to analyze alterations in the her - 2 / neu gene in the study?",
    "answer": "\nThe specific method used to analyze alterations in the **HER-2/neu gene** in the study is not explicitly mentioned in the provided context. To determine the analytical approach (e.g., fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), PCR, or genomic sequencing), additional details about the study's methodology would be required. If you have further information or specific details about the study, feel free to share, and I can refine the answer!",
    "ground_truth": "The study utilized Southern blot analysis to evaluate alterations in the her - 2 / neu gene. Specifically, the paper states: 'dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32 p - labeled her - 2 / neu - 1 probe.' This demonstrates that the researchers employed a molecular technique to detect specific genetic alterations.",
    "source": "'dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32 p - labeled her - 2 / neu - 1 probe.'",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:58:31",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 6.9684898853302
  },
  {
    "id": 4,
    "repeat_id": 2,
    "question": "What method was used to analyze alterations in the her - 2 / neu gene in the study?",
    "answer": "\nThe provided context does not specify the exact method used to analyze **HER-2/neu gene alterations** in the study. Common techniques for such analyses include **fluorescence in situ hybridization (FISH)**, **immunohistochemistry (IHC)**, or **genomic sequencing**, but the study's methodology is not detailed here. If you have additional context or specifics about the study, I can provide a more targeted answer!",
    "ground_truth": "The study utilized Southern blot analysis to evaluate alterations in the her - 2 / neu gene. Specifically, the paper states: 'dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32 p - labeled her - 2 / neu - 1 probe.' This demonstrates that the researchers employed a molecular technique to detect specific genetic alterations.",
    "source": "'dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32 p - labeled her - 2 / neu - 1 probe.'",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:58:38",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 7.316479444503784
  },
  {
    "id": 4,
    "repeat_id": 3,
    "question": "What method was used to analyze alterations in the her - 2 / neu gene in the study?",
    "answer": "\nThe method used to analyze alterations in the **HER-2/NEU gene** in the study is not explicitly stated in the provided context. To determine this, the \"retrieve\" function would need to access the specific study details, which are not included here. If you have additional information or context about the study, please share it, and I can help further!",
    "ground_truth": "The study utilized Southern blot analysis to evaluate alterations in the her - 2 / neu gene. Specifically, the paper states: 'dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32 p - labeled her - 2 / neu - 1 probe.' This demonstrates that the researchers employed a molecular technique to detect specific genetic alterations.",
    "source": "'dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32 p - labeled her - 2 / neu - 1 probe.'",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:58:48",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 9.327895164489746
  },
  {
    "id": 5,
    "repeat_id": 1,
    "question": "What specific technique and probe were used to evaluate alterations in the HER-2/neu gene in breast cancer tumors?",
    "answer": "\nThe specific technique and probe used to evaluate **HER-2/NEU gene alterations** in breast cancer tumors are not detailed in the provided context. However, in standard clinical and research settings, **fluorescence in situ hybridization (FISH)** is a commonly used technique to detect HER-2/neu gene amplification. This method typically employs a **HER-2/neu gene-specific probe** (e.g., labeled with fluorescent dyes) to hybridize with DNA in tumor cells, allowing for the quantification of gene copy numbers. \nIf this question refers to a specific study or dataset, additional context would be needed to provide precise details. Let me know if you'd like further clarification!",
    "ground_truth": "According to the excerpt, Southern blot analysis with a 32P-labeled HER-2/neu-1 probe was used to evaluate alterations in the HER-2/neu gene in breast cancer tumors. Specifically, the paper states: 'dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32p - labeled her - 2 / neu - 1 probe, which is known to detect a 13 - kb hybridizing band in human dna.' This demonstrates that the researchers used a specific molecular biology technique (Southern blot) with a radioactively labeled probe to detect gene amplification in tumor DNA samples.",
    "source": "dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32p - labeled her - 2 / neu - 1 probe, which is known to detect a 13 - kb hybridizing band in human dna.",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 13:58:56",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 8.22003960609436
  },
  {
    "id": 5,
    "repeat_id": 2,
    "question": "What specific technique and probe were used to evaluate alterations in the HER-2/neu gene in breast cancer tumors?",
    "answer": "\nThe specific technique and probe used to evaluate **HER-2/NEU gene alterations** in breast cancer tumors are not detailed in the provided context. However, in standard clinical practice, **fluorescence in situ hybridization (FISH)** is the most common technique used to assess HER-2/neu gene amplification. This method typically employs a **HER-2/neu gene-specific probe** (e.g., a fluorescently labeled DNA probe targeting the HER-2/neu gene locus) to detect copy number variations in tumor cells. \nIf this question relates to a specific study or dataset, additional context would be required to provide precise details. Let me know if you'd like further clarification!",
    "ground_truth": "According to the excerpt, Southern blot analysis with a 32P-labeled HER-2/neu-1 probe was used to evaluate alterations in the HER-2/neu gene in breast cancer tumors. Specifically, the paper states: 'dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32p - labeled her - 2 / neu - 1 probe, which is known to detect a 13 - kb hybridizing band in human dna.' This demonstrates that the researchers used a specific molecular biology technique (Southern blot) with a radioactively labeled probe to detect gene amplification in tumor DNA samples.",
    "source": "dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32p - labeled her - 2 / neu - 1 probe, which is known to detect a 13 - kb hybridizing band in human dna.",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 13:59:03",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 7.506287336349487
  },
  {
    "id": 5,
    "repeat_id": 3,
    "question": "What specific technique and probe were used to evaluate alterations in the HER-2/neu gene in breast cancer tumors?",
    "answer": "\nThe specific technique and probe used to evaluate **HER-2/NEU gene alterations** in breast cancer tumors are not detailed in the provided context. However, in standard clinical and research settings, **fluorescence in situ hybridization (FISH)** is the most widely used technique to assess HER-2/neu gene amplification. This method typically involves a **HER-2/neu gene-specific probe** (e.g., a fluorescently labeled DNA probe targeting the HER-2/neu gene locus) to detect copy number variations in tumor cells. \nIf this question pertains to a specific study or dataset, additional context would be needed to provide precise details. Let me know if you'd like further clarification!",
    "ground_truth": "According to the excerpt, Southern blot analysis with a 32P-labeled HER-2/neu-1 probe was used to evaluate alterations in the HER-2/neu gene in breast cancer tumors. Specifically, the paper states: 'dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32p - labeled her - 2 / neu - 1 probe, which is known to detect a 13 - kb hybridizing band in human dna.' This demonstrates that the researchers used a specific molecular biology technique (Southern blot) with a radioactively labeled probe to detect gene amplification in tumor DNA samples.",
    "source": "dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32p - labeled her - 2 / neu - 1 probe, which is known to detect a 13 - kb hybridizing band in human dna.",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 13:59:12",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 8.185934782028198
  },
  {
    "id": 6,
    "repeat_id": 1,
    "question": "What was observed regarding the HER-2/neu loci in the study?",
    "answer": "\nThe observations regarding the **HER-2/NEU loci** in the study are not specified in the provided context. However, in general research and clinical settings, HER-2/neu gene amplification (often detected via FISH) is commonly associated with **poor prognosis** in breast cancer and is a key biomarker for targeted therapies like trastuzumab. \nIf this question refers to a specific study, additional details about the study's findings would be required to provide accurate information. Let me know if you'd like further clarification!",
    "ground_truth": "The study observed that in two of the three cases, the rearrangement of the HER-2/neu loci was identical, and additionally, two of the rearranged HER-2/neu loci were amplified. Specifically, the excerpt states: 'also, two of the rearranged her - 2 / neu loci were amplified.' This indicates a potential significance of these rearrangements in the context of breast cancer.",
    "source": "'also, two of the rearranged her - 2 / neu loci were amplified.'",
    "difficulty": "medium",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:59:19",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 7.143867254257202
  },
  {
    "id": 6,
    "repeat_id": 2,
    "question": "What was observed regarding the HER-2/neu loci in the study?",
    "answer": "\nThe observations regarding the **HER-2/NEU loci** in the study are not specified in the provided context. Without access to the specific study details or additional information, I cannot confirm the exact findings. However, in general research, HER-2/neu gene amplification (often detected via FISH) is associated with **poor prognosis** in breast cancer and is a key biomarker for targeted therapies. \nIf you have access to the study's full text or specific details, please provide them, and I can help analyze the findings!",
    "ground_truth": "The study observed that in two of the three cases, the rearrangement of the HER-2/neu loci was identical, and additionally, two of the rearranged HER-2/neu loci were amplified. Specifically, the excerpt states: 'also, two of the rearranged her - 2 / neu loci were amplified.' This indicates a potential significance of these rearrangements in the context of breast cancer.",
    "source": "'also, two of the rearranged her - 2 / neu loci were amplified.'",
    "difficulty": "medium",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:59:27",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 7.78298807144165
  },
  {
    "id": 6,
    "repeat_id": 3,
    "question": "What was observed regarding the HER-2/neu loci in the study?",
    "answer": "\nThe observations regarding the **HER-2/NEU loci** in the study are not specified in the provided context. Without access to the specific study details or additional information, I cannot confirm the exact findings. However, in general research, HER-2/neu gene amplification (often detected via FISH) is associated with **poor prognosis** in breast cancer and is a key biomarker for targeted therapies. \nIf you have access to the study's full text or specific details, please provide them, and I can help analyze the findings!",
    "ground_truth": "The study observed that in two of the three cases, the rearrangement of the HER-2/neu loci was identical, and additionally, two of the rearranged HER-2/neu loci were amplified. Specifically, the excerpt states: 'also, two of the rearranged her - 2 / neu loci were amplified.' This indicates a potential significance of these rearrangements in the context of breast cancer.",
    "source": "'also, two of the rearranged her - 2 / neu loci were amplified.'",
    "difficulty": "medium",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:59:34",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 7.769107818603516
  },
  {
    "id": 7,
    "repeat_id": 1,
    "question": "How do the proteins produced by the HER-2/neu and EGFR genes differ in size?",
    "answer": "\nThe proteins produced by the **HER-2/neu** and **EGFR** genes differ in size due to their distinct structures and domains:\n1. **HER-2/neu (ErbB2)**:  \n   - The full-length protein is approximately **185 kDa (kilodaltons)**.  \n   - It is a transmembrane receptor tyrosine kinase with a large extracellular domain, a transmembrane segment, and an intracellular kinase domain.  \n2. **EGFR (ErbB1)**:  \n   - The mature, full-length protein is approximately **170 kDa**.  \n   - It has a smaller extracellular domain compared to HER-2/neu, but it also includes an extracellular ligand-binding region and an intracellular kinase domain.  \n### Key Difference:  \n- **HER-2/neu** is **larger** than **EGFR** due to its extended extracellular domain, which includes additional regions for ligand binding and dimerization.  \n### Note:  \nVariations in size may occur due to alternative splicing or post-translational modifications, but the standard sizes cited above are based on the most common isoforms.",
    "ground_truth": "According to the excerpt, the protein encoded by the HER-2/neu gene is larger than the protein encoded by the EGFR gene. Specifically, the paper states that the HER-2/neu protein is \"185,000 daltons, as compared to the 170,000-dalton protein encoded by the egfr gene.\"",
    "source": "finally, the protein encoded by the her - 2 / neu gene is 185, 000 daltons, as compared to the 170, 000 - dalton protein encoded by the egfr gene.",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:59:45",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 10.593007802963257
  },
  {
    "id": 7,
    "repeat_id": 2,
    "question": "How do the proteins produced by the HER-2/neu and EGFR genes differ in size?",
    "answer": "\nThe proteins produced by the **HER-2/neu** and **EGFR** genes differ in size due to structural differences in their extracellular domains:\n- **HER-2/neu (ErbB2)**:  \n  - **Molecular weight**: ~**185 kDa**.  \n  - Features a larger extracellular domain compared to EGFR, which includes additional regions for dimerization and ligand binding.  \n- **EGFR (ErbB1)**:  \n  - **Molecular weight**: ~**170 kDa**.  \n  - Has a smaller extracellular domain, with a ligand-binding region and a transmembrane segment.  \n### Summary:  \n**HER-2/neu** is **larger** than **EGFR** by approximately **15 kDa**, primarily due to its extended extracellular domain. This structural difference influences their functional interactions and signaling properties.",
    "ground_truth": "According to the excerpt, the protein encoded by the HER-2/neu gene is larger than the protein encoded by the EGFR gene. Specifically, the paper states that the HER-2/neu protein is \"185,000 daltons, as compared to the 170,000-dalton protein encoded by the egfr gene.\"",
    "source": "finally, the protein encoded by the her - 2 / neu gene is 185, 000 daltons, as compared to the 170, 000 - dalton protein encoded by the egfr gene.",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:59:55",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 9.894465446472168
  },
  {
    "id": 7,
    "repeat_id": 3,
    "question": "How do the proteins produced by the HER-2/neu and EGFR genes differ in size?",
    "answer": "\nThe proteins produced by the **HER-2/neu** and **EGFR** genes differ in size due to structural differences in their extracellular domains:\n- **HER-2/neu (ErbB2)**:  \n  - **Molecular weight**: ~**185 kDa**.  \n  - Features a larger extracellular domain compared to EGFR, which includes additional regions for dimerization and ligand binding.  \n- **EGFR (ErbB1)**:  \n  - **Molecular weight**: ~**170 kDa**.  \n  - Has a smaller extracellular domain, with a ligand-binding region and a transmembrane segment.  \n### Summary:  \n**HER-2/neu** is **larger** than **EGFR** by approximately **15 kDa**, primarily due to its extended extracellular domain. This structural difference influences their functional interactions and signaling properties.",
    "ground_truth": "According to the excerpt, the protein encoded by the HER-2/neu gene is larger than the protein encoded by the EGFR gene. Specifically, the paper states that the HER-2/neu protein is \"185,000 daltons, as compared to the 170,000-dalton protein encoded by the egfr gene.\"",
    "source": "finally, the protein encoded by the her - 2 / neu gene is 185, 000 daltons, as compared to the 170, 000 - dalton protein encoded by the egfr gene.",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 14:00:05",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 9.730126142501831
  },
  {
    "id": 8,
    "repeat_id": 1,
    "question": "What impact does HER-2/neu amplification have on overall survival and relapse in node-positive breast cancer patients according to the excerpt?",
    "answer": "\nThe provided conversation history does not include a specific excerpt or study details about HER-2/neu amplification's impact on overall survival and relapse in node-positive breast cancer patients. However, based on general oncological knowledge:\n- **HER-2/neu amplification** (a marker of overactive HER2 signaling) is associated with **poorer prognosis** in breast cancer, including **higher relapse rates** and **reduced overall survival** in node-positive cases.  \n- Amplification often correlates with **aggressive tumor behavior**, resistance to certain therapies, and a need for targeted treatments like **trastuzumab** (Herceptin) to improve outcomes.  \nIf you have a specific excerpt or study in mind, please provide details for a more precise answer!",
    "ground_truth": "The excerpt indicates that patients with HER-2/neu amplification have significantly different outcomes compared to those without amplification. Specifically, it states: 'the curves dramatically show that patients with her - 2 / neu'. This suggests that higher levels of HER-2/neu amplification correlate with poorer overall survival and increased relapse rates in node-positive patients.",
    "source": "'the curves dramatically show that patients with her - 2 / neu'",
    "difficulty": "easy",
    "confidence": "medium",
    "timestamp": "2025-05-14 14:00:13",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 8.708089351654053
  },
  {
    "id": 8,
    "repeat_id": 2,
    "question": "What impact does HER-2/neu amplification have on overall survival and relapse in node-positive breast cancer patients according to the excerpt?",
    "answer": "\nThe provided conversation history does not include a specific excerpt or study details about HER-2/neu amplification's impact on overall survival and relapse in node-positive breast cancer patients. However, based on general oncological knowledge:\n- **HER-2/neu amplification** (a marker of overactive HER2 signaling) is associated with **poorer prognosis** in breast cancer, including **higher relapse rates** and **reduced overall survival** in node-positive cases.  \n- Amplification often correlates with **aggressive tumor behavior**, resistance to certain therapies, and a need for targeted treatments like **trastuzumab** (Herceptin) to improve outcomes.  \nIf you have a specific excerpt or study in mind, please provide details for a more precise answer!",
    "ground_truth": "The excerpt indicates that patients with HER-2/neu amplification have significantly different outcomes compared to those without amplification. Specifically, it states: 'the curves dramatically show that patients with her - 2 / neu'. This suggests that higher levels of HER-2/neu amplification correlate with poorer overall survival and increased relapse rates in node-positive patients.",
    "source": "'the curves dramatically show that patients with her - 2 / neu'",
    "difficulty": "easy",
    "confidence": "medium",
    "timestamp": "2025-05-14 14:00:22",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 8.24915862083435
  },
  {
    "id": 8,
    "repeat_id": 3,
    "question": "What impact does HER-2/neu amplification have on overall survival and relapse in node-positive breast cancer patients according to the excerpt?",
    "answer": "\nThe provided conversation history does not include a specific excerpt or study details about HER-2/neu amplification's impact on overall survival and relapse in node-positive breast cancer patients. However, based on general oncological knowledge:\n- **HER-2/neu amplification** (a marker of overactive HER2 signaling) is associated with **poorer prognosis** in breast cancer, including **higher relapse rates** and **reduced overall survival** in node-positive cases.  \n- Amplification often correlates with **aggressive tumor behavior**, resistance to certain therapies, and a need for targeted treatments like **trastuzumab** (Herceptin) to improve outcomes.  \nIf you have a specific excerpt or study in mind, please provide details for a more precise answer!",
    "ground_truth": "The excerpt indicates that patients with HER-2/neu amplification have significantly different outcomes compared to those without amplification. Specifically, it states: 'the curves dramatically show that patients with her - 2 / neu'. This suggests that higher levels of HER-2/neu amplification correlate with poorer overall survival and increased relapse rates in node-positive patients.",
    "source": "'the curves dramatically show that patients with her - 2 / neu'",
    "difficulty": "easy",
    "confidence": "medium",
    "timestamp": "2025-05-14 14:00:30",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 8.201534271240234
  },
  {
    "id": 9,
    "repeat_id": 1,
    "question": "What impact does HER-2/neu gene amplification have on patient outcomes according to the excerpt?",
    "answer": "\nThe provided conversation history does not include a specific excerpt or study details about HER-2/neu amplification's impact on patient outcomes. However, based on general oncological knowledge:\n- **HER-2/neu amplification** is strongly linked to **poorer patient outcomes**, including **reduced overall survival** and **increased risk of relapse**, particularly in node-positive breast cancer.  \n- It is a key biomarker for selecting targeted therapies (e.g., trastuzumab) to improve survival and reduce recurrence risks.  \nIf you have a specific excerpt or study in mind, please provide details for a more precise answer!",
    "ground_truth": "The excerpt indicates that patients with HER-2/neu gene amplification, particularly those with more than 5 copies, had significantly worse outcomes. Specifically, it states: 'patients with greater than five copies of her - 2 / neu had even shorter disease - free survival times (p = 0. 015) and overall survival times (p = 0. 06)'. This demonstrates that higher levels of gene amplification correlate with poorer survival rates.",
    "source": "'patients with greater than five copies of her - 2 / neu had even shorter disease - free survival times (p = 0. 015) and overall survival times (p = 0. 06)'",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 14:00:37",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 7.479374408721924
  },
  {
    "id": 9,
    "repeat_id": 2,
    "question": "What impact does HER-2/neu gene amplification have on patient outcomes according to the excerpt?",
    "answer": "\nThe provided conversation history does not include a specific excerpt or study details about HER-2/neu amplification's impact on patient outcomes. However, based on general oncological knowledge:\n- **HER-2/neu amplification** is strongly linked to **poorer patient outcomes**, including **reduced overall survival** and **increased risk of relapse**, particularly in node-positive breast cancer.  \n- It is a key biomarker for selecting targeted therapies (e.g., trastuzumab) to improve survival and reduce recurrence risks.  \nIf you have a specific excerpt or study in mind, please provide details for a more precise answer!",
    "ground_truth": "The excerpt indicates that patients with HER-2/neu gene amplification, particularly those with more than 5 copies, had significantly worse outcomes. Specifically, it states: 'patients with greater than five copies of her - 2 / neu had even shorter disease - free survival times (p = 0. 015) and overall survival times (p = 0. 06)'. This demonstrates that higher levels of gene amplification correlate with poorer survival rates.",
    "source": "'patients with greater than five copies of her - 2 / neu had even shorter disease - free survival times (p = 0. 015) and overall survival times (p = 0. 06)'",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 14:00:45",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 7.382110834121704
  },
  {
    "id": 9,
    "repeat_id": 3,
    "question": "What impact does HER-2/neu gene amplification have on patient outcomes according to the excerpt?",
    "answer": "\nThe provided conversation history does not include a specific excerpt or study details about HER-2/neu amplification's impact on patient outcomes. However, based on general oncological knowledge:\n- **HER-2/neu amplification** is strongly linked to **poorer patient outcomes**, including **reduced overall survival** and **increased risk of relapse**, particularly in node-positive breast cancer.  \n- It is a key biomarker for selecting targeted therapies (e.g., trastuzumab) to improve survival and reduce recurrence risks.  \nIf you have a specific excerpt or study in mind, please provide details for a more precise answer!",
    "ground_truth": "The excerpt indicates that patients with HER-2/neu gene amplification, particularly those with more than 5 copies, had significantly worse outcomes. Specifically, it states: 'patients with greater than five copies of her - 2 / neu had even shorter disease - free survival times (p = 0. 015) and overall survival times (p = 0. 06)'. This demonstrates that higher levels of gene amplification correlate with poorer survival rates.",
    "source": "'patients with greater than five copies of her - 2 / neu had even shorter disease - free survival times (p = 0. 015) and overall survival times (p = 0. 06)'",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 14:00:51",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 6.346437454223633
  },
  {
    "id": 10,
    "repeat_id": 1,
    "question": "What types of evidence support the link between proto-oncogenes and human malignancies according to the excerpt?",
    "answer": "\nThe provided conversation history does not include a specific excerpt or study details about evidence linking proto-oncogenes to human malignancies. However, based on general oncological knowledge, the following types of evidence typically support this link:\n1. **Genetic Mutations**: Activating mutations in proto-oncogenes (e.g., *RAS*, *MYC*) are frequently observed in human cancers.  \n2. **Chromosomal Abnormalities**: Amplifications, translocations, or deletions involving proto-oncogenes (e.g., *BCR-ABL* in CML) are associated with malignancies.  \n3. **Overexpression**: Overexpression of proto-oncogene products (e.g., *HER2* in breast cancer) correlates with tumor progression.  \n4. **Functional Studies**: Experimental models (e.g., transgenic mice) show that proto-oncogene activation drives tumorigenesis.  \n5. **Clinical Correlations**: Prognostic or predictive associations between proto-oncogene activity and cancer outcomes (e.g., *EGFR* in lung cancer).  \nIf you have a specific excerpt or study in mind, please provide details for a more precise answer!",
    "ground_truth": "The excerpt outlines several types of evidence that support the link between proto-oncogenes and human malignancies. It states that this evidence is derived from 'studies of animal models, tumor cell lines, and actual human tumors.' Additionally, it mentions specific data including 'sequence homology between human proto-oncogenes and the viral oncogenes of transforming retroviruses,' 'transfection studies showing the transforming potential of proto-oncogenes in nih 3 t 3 cells and primary embryo fibroblasts,' and 'the central role of certain proto-oncogenes in tumorigen.' This demonstrates that the relationship is supported by both experimental and comparative studies.",
    "source": "'the evidence linking proto - oncogenes to the induction or maintenance of human malignancies is largely circumstantial, but has become increasingly compelling. this circumstantial evidence is derived from studies of animal models, tumor cell lines, and actual human tumors.'",
    "difficulty": "medium",
    "confidence": "medium",
    "timestamp": "2025-05-14 14:01:01",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 9.825647115707397
  },
  {
    "id": 10,
    "repeat_id": 2,
    "question": "What types of evidence support the link between proto-oncogenes and human malignancies according to the excerpt?",
    "answer": "\nThe provided conversation history does not include a specific excerpt or study details about evidence linking proto-oncogenes to human malignancies. However, based on general oncological knowledge, the following types of evidence typically support this link:\n1. **Genetic Mutations**: Activating mutations in proto-oncogenes (e.g., *RAS*, *MYC*) are frequently observed in human cancers.  \n2. **Chromosomal Abnormalities**: Amplifications, translocations, or deletions involving proto-oncogenes (e.g., *BCR-ABL* in CML) are associated with malignancies.  \n3. **Overexpression**: Overexpression of proto-oncogene products (e.g., *HER2* in breast cancer) correlates with tumor progression.  \n4. **Functional Studies**: Experimental models (e.g., transgenic mice) show that proto-oncogene activation drives tumorigenesis.  \n5. **Clinical Correlations**: Prognostic or predictive associations between proto-oncogene activity and cancer outcomes (e.g., *EGFR* in lung cancer).  \nIf you have a specific excerpt or study in mind, please provide details for a more precise answer!",
    "ground_truth": "The excerpt outlines several types of evidence that support the link between proto-oncogenes and human malignancies. It states that this evidence is derived from 'studies of animal models, tumor cell lines, and actual human tumors.' Additionally, it mentions specific data including 'sequence homology between human proto-oncogenes and the viral oncogenes of transforming retroviruses,' 'transfection studies showing the transforming potential of proto-oncogenes in nih 3 t 3 cells and primary embryo fibroblasts,' and 'the central role of certain proto-oncogenes in tumorigen.' This demonstrates that the relationship is supported by both experimental and comparative studies.",
    "source": "'the evidence linking proto - oncogenes to the induction or maintenance of human malignancies is largely circumstantial, but has become increasingly compelling. this circumstantial evidence is derived from studies of animal models, tumor cell lines, and actual human tumors.'",
    "difficulty": "medium",
    "confidence": "medium",
    "timestamp": "2025-05-14 14:01:10",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 8.9408597946167
  },
  {
    "id": 10,
    "repeat_id": 3,
    "question": "What types of evidence support the link between proto-oncogenes and human malignancies according to the excerpt?",
    "answer": "\nThe provided conversation history does not include a specific excerpt or study details about evidence linking proto-oncogenes to human malignancies. However, based on general oncological knowledge, the following types of evidence typically support this link:\n1. **Genetic Mutations**: Activating mutations in proto-oncogenes (e.g., *RAS*, *MYC*) are frequently observed in human cancers.  \n2. **Chromosomal Abnormalities**: Amplifications, translocations, or deletions involving proto-oncogenes (e.g., *BCR-ABL* in CML) are associated with malignancies.  \n3. **Overexpression**: Overexpression of proto-oncogene products (e.g., *HER2* in breast cancer) correlates with tumor progression.  \n4. **Functional Studies**: Experimental models (e.g., transgenic mice) show that proto-oncogene activation drives tumorigenesis.  \n5. **Clinical Correlations**: Prognostic or predictive associations between proto-oncogene activity and cancer outcomes (e.g., *EGFR* in lung cancer).  \nIf you have a specific excerpt or study in mind, please provide details for a more precise answer!",
    "ground_truth": "The excerpt outlines several types of evidence that support the link between proto-oncogenes and human malignancies. It states that this evidence is derived from 'studies of animal models, tumor cell lines, and actual human tumors.' Additionally, it mentions specific data including 'sequence homology between human proto-oncogenes and the viral oncogenes of transforming retroviruses,' 'transfection studies showing the transforming potential of proto-oncogenes in nih 3 t 3 cells and primary embryo fibroblasts,' and 'the central role of certain proto-oncogenes in tumorigen.' This demonstrates that the relationship is supported by both experimental and comparative studies.",
    "source": "'the evidence linking proto - oncogenes to the induction or maintenance of human malignancies is largely circumstantial, but has become increasingly compelling. this circumstantial evidence is derived from studies of animal models, tumor cell lines, and actual human tumors.'",
    "difficulty": "medium",
    "confidence": "medium",
    "timestamp": "2025-05-14 14:01:19",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 8.983467102050781
  },
  {
    "id": 11,
    "repeat_id": 1,
    "question": "How does HER-2/neu gene amplification impact prognosis in breast cancer patients, and how does its prognostic value compare to other factors?",
    "answer": "\nHER-2/neu gene amplification significantly impacts prognosis in breast cancer patients, particularly in the context of **HER2-positive tumors**. Here's a breakdown of its prognostic implications and how it compares to other factors:\n---\n### **1. Impact of HER-2/neu Amplification on Prognosis**\n- **Aggressive Biology**: HER2-positive breast cancers are typically more aggressive, with higher proliferation rates, faster tumor growth, and a higher likelihood of recurrence compared to HER2-negative tumors.\n- **Poorer Survival Outcomes**: \n  - **Node-positive disease**: HER2-positive tumors are associated with **worse survival** in node-positive patients, even when compared to ER-positive tumors of similar stage.\n  - **Node-negative disease**: While HER2-positive tumors in node-negative patients may have similar 5-year survival rates to ER-positive tumors, they carry a **higher risk of recurrence** and are more likely to progress to advanced stages.\n- **Response to Therapy**: HER2-positive tumors are **responsive to targeted therapies** (e.g., trastuzumab, pertuzumab), which have improved outcomes for these patients. However, the presence of HER2 amplification itself is a **negative prognostic factor** without treatment.\n---\n### **2. Comparison to Other Prognostic Factors**\nHER-2/neu status is one of several critical factors used in breast cancer prognosis. Here's how it compares to others:\n| **Factor**                | **Prognostic Impact**                                                                 | **Comparison to HER2 Status**                                                                 |\n|---------------------------|----------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|\n| **Hormone Receptor Status** (ER/PR) | ER-positive tumors generally have **better prognosis** than HER2-positive or triple-negative tumors. | HER2-positive tumors often have **worse outcomes** than ER-positive tumors, even in similar stages. |\n| **Tumor Stage** (TNM)     | Higher stages (e.g., node-positive, stage III) are associated with **poorer survival**. | HER2-positive tumors in node-positive patients have **worse survival** than ER-positive tumors of the same stage. |\n| **Ki-67 Expression**      | High Ki-67 (proliferative index) indicates **aggressive tumors**.                    | HER2-positive tumors often have **higher Ki-67 levels** than ER-positive tumors, reflecting their aggressiveness. |\n| **Triple-Negative Status** | Triple-negative breast cancers (ER/PR/HER2-negative) have **poor prognosis**.         | HER2-positive tumors may have **similar or worse outcomes** than triple-negative tumors, depending on stage and other factors. |\n| **Genomic Profiling**     | Tools like Oncotype DX or MammaPrint assess **recurrence risk**.                      | HER2 status is a **key component** of genomic profiling, but it is often combined with other markers (e.g., ER, Ki-67) to refine risk stratification. |\n---\n### **3. Clinical Relevance**\n- **HER2 as a Biomarker**: HER2 status is a **mandatory part of breast cancer staging** (per TNM guidelines) and guides treatment decisions (e.g., targeted therapies).\n- **Combined Prognostic Factors**: HER2 status is **integrated with other factors** (e.g., hormone receptor status, tumor size, lymph node involvement) to determine **risk stratification** and **personalized treatment plans**.\n- **Therapeutic Implications**: While HER2 amplification is a negative prognostic factor, **targeted therapies** have transformed outcomes for HER2-positive patients, highlighting the importance of **early detection and tailored treatment**.\n---\n### **Summary**\nHER-2/neu amplification is a **strong negative prognostic factor** in breast cancer, particularly in node-positive cases. However, its prognostic value is **context-dependent** and often **compared to other factors** like hormone receptor status, tumor stage, and genomic markers. While HER2-positive tumors tend to have worse outcomes than ER-positive tumors, advances in targeted therapies have improved survival for these patients, underscoring the importance of **integrating HER2 status into comprehensive clinical decision-making**.",
    "ground_truth": "According to the excerpt, HER-2/neu gene amplification is a significant predictor of both overall survival and time to relapse in breast cancer patients. The study found that it retained its significance even when adjusted for other known prognostic factors. Notably, HER-2/neu amplification showed greater prognostic value than most currently used factors, including hormonal-receptor status, particularly in lymph node-positive disease. This suggests that the HER-2/neu gene may play a crucial role in the biological behavior and/or pathogenesis of human breast cancer.",
    "source": "amplification of the her - 2 / neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer. it retained its significance even when adjustments were made for other known prognostic factors. moreover, her - 2 / neu amplification had greater prognostic value than most currently used prognostic factors, including hormonal - receptor status, in lymph node - positive disease. these data indicate that this gene may play a role in the biologic behavior and / or pathogenesis of human breast cancer.",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 14:01:44",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 25.380679845809937
  },
  {
    "id": 11,
    "repeat_id": 2,
    "question": "How does HER-2/neu gene amplification impact prognosis in breast cancer patients, and how does its prognostic value compare to other factors?",
    "answer": "\nHER-2/neu gene amplification (HER2 positivity) significantly impacts the prognosis of breast cancer patients, but its prognostic value is context-dependent and often compared to other factors like hormone receptor status, tumor stage, and genomic markers. Here's a structured breakdown:\n---\n### **1. Impact of HER-2/neu Amplification on Prognosis**\n- **Aggressive Biology**: HER2-positive tumors are generally **more aggressive** than ER-positive or PR-positive tumors, characterized by rapid growth, higher proliferation rates (e.g., high Ki-67), and a tendency to recur or metastasize.\n- **Node-Positive Patients**: In **node-positive** (stage II/III) breast cancer, HER2-positive tumors have **worse survival outcomes** compared to ER-positive tumors of similar stage. This is due to their higher likelihood of lymph node involvement and resistance to traditional therapies.\n- **Node-Negative Patients**: While HER2-positive tumors in **node-negative** (stage I/II) patients may have similar 5-year survival rates to ER-positive tumors, they carry a **higher risk of recurrence** and are more likely to progress to advanced stages.\n- **Response to Therapy**: HER2-positive tumors are **responsive to targeted therapies** (e.g., trastuzumab, pertuzumab), which have improved survival for these patients. However, the presence of HER2 amplification itself remains a **negative prognostic factor** without treatment.\n---\n### **2. Comparison to Other Prognostic Factors**\n| **Factor**                | **Prognostic Impact**                                                                 | **Comparison to HER2 Status**                                                                 |\n|---------------------------|----------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|\n| **Hormone Receptor Status** (ER/PR) | ER-positive tumors generally have **better prognosis** than HER2-positive or triple-negative tumors. | HER2-positive tumors often have **worse outcomes** than ER-positive tumors, even in similar stages. |\n| **Tumor Stage** (TNM)     | Higher stages (e.g., node-positive, stage III) are associated with **poorer survival**. | HER2-positive tumors in node-positive patients have **worse survival** than ER-positive tumors of the same stage. |\n| **Ki-67 Expression**      | High Ki-67 (proliferative index) indicates **aggressive tumors**.                    | HER2-positive tumors often have **higher Ki-67 levels** than ER-positive tumors, reflecting their aggressiveness. |\n| **Triple-Negative Status** | Triple-negative breast cancers (ER/PR/HER2-negative) have **poor prognosis**.         | HER2-positive tumors may have **similar or worse outcomes** than triple-negative tumors, depending on stage and other factors. |\n| **Genomic Profiling**     | Tools like Oncotype DX or MammaPrint assess **recurrence risk**.                      | HER2 status is a **key component** of genomic profiling, but it is often combined with other markers (e.g., ER, Ki-67) to refine risk stratification. |\n---\n### **3. Clinical Relevance**\n- **HER2 as a Biomarker**: HER2 status is a **mandatory part of breast cancer staging** (per TNM guidelines) and guides treatment decisions (e.g., targeted therapies).\n- **Therapeutic Implications**: While HER2 amplification is a negative prognostic factor, **targeted therapies** have transformed outcomes for HER2-positive patients, highlighting the importance of **early detection and tailored treatment**.\n- **Combined Prognostic Factors**: HER2 status is **integrated with other factors** (e.g., hormone receptor status, tumor size, lymph node involvement) to determine **risk stratification** and **personalized treatment plans**.\n---\n### **Summary**\nHER-2/neu amplification is a **strong negative prognostic factor** in breast cancer, particularly in node-positive cases. However, its prognostic value is **context-dependent** and often **compared to other factors** like hormone receptor status, tumor stage, and genomic markers. While HER2-positive tumors tend to have worse outcomes than ER-positive tumors, advances in targeted therapies have improved survival for these patients, underscoring the importance of **integrating HER2 status into comprehensive clinical decision-making**.",
    "ground_truth": "According to the excerpt, HER-2/neu gene amplification is a significant predictor of both overall survival and time to relapse in breast cancer patients. The study found that it retained its significance even when adjusted for other known prognostic factors. Notably, HER-2/neu amplification showed greater prognostic value than most currently used factors, including hormonal-receptor status, particularly in lymph node-positive disease. This suggests that the HER-2/neu gene may play a crucial role in the biological behavior and/or pathogenesis of human breast cancer.",
    "source": "amplification of the her - 2 / neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer. it retained its significance even when adjustments were made for other known prognostic factors. moreover, her - 2 / neu amplification had greater prognostic value than most currently used prognostic factors, including hormonal - receptor status, in lymph node - positive disease. these data indicate that this gene may play a role in the biologic behavior and / or pathogenesis of human breast cancer.",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 14:02:09",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 24.901450634002686
  },
  {
    "id": 11,
    "repeat_id": 3,
    "question": "How does HER-2/neu gene amplification impact prognosis in breast cancer patients, and how does its prognostic value compare to other factors?",
    "answer": "\nHER-2/neu gene amplification (HER2 positivity) significantly impacts the prognosis of breast cancer patients, but its prognostic value is context-dependent and often compared to other factors like hormone receptor status, tumor stage, and genomic markers. Here's a structured breakdown:\n---\n### **1. Impact of HER-2/neu Amplification on Prognosis**\n- **Aggressive Biology**: HER2-positive tumors are generally **more aggressive** than ER-positive or PR-positive tumors, characterized by rapid growth, higher proliferation rates (e.g., high Ki-67), and a tendency to recur or metastasize.\n- **Node-Positive Patients**: In **node-positive** (stage II/III) breast cancer, HER2-positive tumors have **worse survival outcomes** compared to ER-positive tumors of similar stage. This is due to their higher likelihood of lymph node involvement and resistance to traditional therapies.\n- **Node-Negative Patients**: While HER2-positive tumors in **node-negative** (stage I/II) patients may have similar 5-year survival rates to ER-positive tumors, they carry a **higher risk of recurrence** and are more likely to progress to advanced stages.\n- **Response to Therapy**: HER2-positive tumors are **responsive to targeted therapies** (e.g., trastuzumab, pertuzumab), which have improved survival for these patients. However, the presence of HER2 amplification itself remains a **negative prognostic factor** without treatment.\n---\n### **2. Comparison to Other Prognostic Factors**\n| **Factor**                | **Prognostic Impact**                                                                 | **Comparison to HER2 Status**                                                                 |\n|---------------------------|----------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|\n| **Hormone Receptor Status** (ER/PR) | ER-positive tumors generally have **better prognosis** than HER2-positive or triple-negative tumors. | HER2-positive tumors tend to have **worse outcomes** than ER-positive tumors, especially in node-positive cases. |\n| **Tumor Stage**           | Advanced stages (e.g., stage III) are associated with poorer survival.                | HER2 amplification **exacerbates** the poor prognosis of advanced-stage tumors.            |\n| **Genomic Profiling**     | Tools like Oncotype DX or MammaPrint assess **recurrence risk**.                      | HER2 status is a **key component** of genomic profiling, but it is often combined with other markers (e.g., ER, Ki-67) to refine risk stratification. |\n---\n### **3. Clinical Relevance**\n- **HER2 as a Biomarker**: HER2 status is a **mandatory part of breast cancer staging** (per TNM guidelines) and guides treatment decisions (e.g., targeted therapies).\n- **Therapeutic Implications**: While HER2 amplification is a negative prognostic factor, **targeted therapies** have transformed outcomes for HER2-positive patients, highlighting the importance of **early detection and tailored treatment**.\n- **Combined Prognostic Factors**: HER2 status is **integrated with other factors** (e.g., hormone receptor status, tumor size, lymph node involvement) to determine **risk stratification** and **personalized treatment plans**.\n---\n### **Summary**\nHER-2/neu amplification is a **strong negative prognostic factor** in breast cancer, particularly in node-positive cases. However, its prognostic value is **context-dependent** and often **compared to other factors** like hormone receptor status, tumor stage, and genomic markers. While HER2-positive tumors tend to have worse outcomes than ER-positive tumors, advances in targeted therapies have improved survival for these patients, underscoring the importance of **integrating HER2 status into comprehensive clinical decision-making**.",
    "ground_truth": "According to the excerpt, HER-2/neu gene amplification is a significant predictor of both overall survival and time to relapse in breast cancer patients. The study found that it retained its significance even when adjusted for other known prognostic factors. Notably, HER-2/neu amplification showed greater prognostic value than most currently used factors, including hormonal-receptor status, particularly in lymph node-positive disease. This suggests that the HER-2/neu gene may play a crucial role in the biological behavior and/or pathogenesis of human breast cancer.",
    "source": "amplification of the her - 2 / neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer. it retained its significance even when adjustments were made for other known prognostic factors. moreover, her - 2 / neu amplification had greater prognostic value than most currently used prognostic factors, including hormonal - receptor status, in lymph node - positive disease. these data indicate that this gene may play a role in the biologic behavior and / or pathogenesis of human breast cancer.",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 14:02:31",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 22.14836883544922
  },
  {
    "id": 12,
    "repeat_id": 1,
    "question": "How does HER-2/neu gene amplification relate to patient prognosis in node-positive breast cancer cases?",
    "answer": "\nIn **node-positive breast cancer** (tumors with lymph node involvement, typically stages II or III), **HER-2/neu gene amplification** (HER2 positivity) is a **strong negative prognostic factor** and is associated with distinct clinical outcomes compared to other subtypes. Here's a detailed breakdown:\n---\n### **1. Prognostic Impact of HER2 in Node-Positive Cases**\n- **Worse Survival Outcomes**: HER2-positive node-positive tumors are associated with **poorer survival** compared to **ER-positive node-positive tumors** of similar stage. This is due to:\n  - Higher proliferation rates (e.g., elevated Ki-67).\n  - Greater likelihood of distant metastasis.\n  - Resistance to traditional chemotherapy in some cases.\n- **Recurrence Risk**: HER2-positive node-positive tumors have a **higher risk of recurrence** even after standard adjuvant therapy, necessitating more aggressive treatment strategies.\n---\n### **2. Comparison to Other Prognostic Factors**\n| **Factor**                | **Prognostic Impact in Node-Positive Cases** | **Comparison to HER2 Status**                                                                 |\n|---------------------------|------------------------------------------------|------------------------------------------------------------------------------------------------|\n| **Hormone Receptor Status** (ER/PR) | ER-positive node-positive tumors generally have **better survival** than HER2-positive or triple-negative tumors. | HER2-positive tumors have **worse outcomes** than ER-positive tumors, even in node-positive cases. |\n| **Tumor Stage**           | Advanced stages (e.g., stage III) are associated with poorer survival. | HER2 amplification **exacerbates** the poor prognosis of advanced-stage tumors.               |\n| **Genomic Markers**       | High Ki-67 or genomic instability (e.g., Oncotype DX scores) indicate poor prognosis. | HER2 positivity is a **key component** of genomic profiling, but it is often combined with other markers (e.g., Ki-67, hormone receptor status) to refine risk stratification. |\n---\n### **3. Role of Targeted Therapies**\n- **Improved Outcomes**: The introduction of **HER2-targeted therapies** (e.g., trastuzumab, pertuzumab, T-DM1) has significantly improved survival for HER2-positive node-positive patients. These therapies:\n  - Reduce the risk of recurrence.\n  - Improve disease-free survival (DFS) and overall survival (OS) when added to standard chemotherapy.\n- **Treatment Paradigm**: HER2 status is now a **critical determinant** of treatment decisions in node-positive breast cancer, with HER2-positive patients typically receiving **chemotherapy + targeted therapy** (e.g., neoadjuvant or adjuvant settings).\n---\n### **4. Key Takeaways**\n- **HER2-positive node-positive breast cancer** is associated with **poorer prognosis** compared to ER-positive node-positive tumors.\n- **HER2 status** is a **strong independent predictor** of outcome in node-positive cases, even when adjusted for other factors.\n- **Targeted therapies** have transformed the management of HER2-positive node-positive breast cancer, improving survival and reducing recurrence risk.\nIn summary, HER-2/neu gene amplification in node-positive breast cancer is a **negative prognostic factor** but is now **manageable with targeted therapies**, highlighting the importance of HER2 status in treatment planning and risk stratification.",
    "ground_truth": "The excerpt indicates that amplification of the HER-2/neu gene is a strong prognostic factor for patients with node-positive breast cancer. Specifically, it states: 'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients.' This demonstrates that HER-2/neu amplification is significant in predicting disease behavior, even when considering other prognostic factors.",
    "source": "'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients, even when other prognostic factors were taken into account'",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 14:02:54",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 22.762890577316284
  },
  {
    "id": 12,
    "repeat_id": 2,
    "question": "How does HER-2/neu gene amplification relate to patient prognosis in node-positive breast cancer cases?",
    "answer": "\nIn **node-positive breast cancer**, **HER-2/neu gene amplification** (HER2 positivity) is a **negative prognostic factor**, associated with:\n- **Higher risk of recurrence** and **poorer survival** compared to ER-positive node-positive tumors.\n- **Aggressive tumor behavior**, including increased proliferation (e.g., high Ki-67) and metastatic potential.\n- **Worse outcomes** even when adjusted for tumor stage and other markers.\n**Key clinical implications**:\n- HER2-positive node-positive tumors are **more resistant to standard chemotherapy** and require **targeted therapies** (e.g., trastuzumab, pertuzumab) to improve survival.\n- HER2 status is a **critical determinant** of treatment decisions and prognosis in this subgroup.\nIn summary, HER2 amplification worsens prognosis in node-positive breast cancer but is now **manageable with modern therapies**, underscoring its importance in risk stratification and treatment planning.",
    "ground_truth": "The excerpt indicates that amplification of the HER-2/neu gene is a strong prognostic factor for patients with node-positive breast cancer. Specifically, it states: 'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients.' This demonstrates that HER-2/neu amplification is significant in predicting disease behavior, even when considering other prognostic factors.",
    "source": "'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients, even when other prognostic factors were taken into account'",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 14:03:03",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 9.292492628097534
  },
  {
    "id": 12,
    "repeat_id": 3,
    "question": "How does HER-2/neu gene amplification relate to patient prognosis in node-positive breast cancer cases?",
    "answer": "\nIn **node-positive breast cancer**, **HER-2/neu gene amplification** (HER2 positivity) is strongly associated with:\n- **Poorer prognosis** compared to ER-positive node-positive tumors of similar stage.\n- **Higher risk of recurrence** and **reduced overall survival** due to aggressive tumor biology (e.g., high proliferation rates, metastatic potential).\n- **Resistance to conventional chemotherapy** in some cases, necessitating **HER2-targeted therapies** (e.g., trastuzumab) to improve outcomes.\n**Summary**: HER2 amplification worsens prognosis in node-positive breast cancer but is now a treatable factor with modern therapies, making HER2 status a critical biomarker for prognosis and treatment.",
    "ground_truth": "The excerpt indicates that amplification of the HER-2/neu gene is a strong prognostic factor for patients with node-positive breast cancer. Specifically, it states: 'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients.' This demonstrates that HER-2/neu amplification is significant in predicting disease behavior, even when considering other prognostic factors.",
    "source": "'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients, even when other prognostic factors were taken into account'",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 14:03:10",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 6.8066160678863525
  },
  {
    "id": 13,
    "repeat_id": 1,
    "question": "What is the statistical significance of HER-2/neu as a prognostic factor for relapse in node-positive breast cancer patients according to the multivariate analysis?",
    "answer": "\nAccording to the **multivariate analysis** in the study, **HER-2/neu amplification** showed **statistically significant** associations with relapse in node-positive breast cancer patients:  \n- **P-value for relapse**: **<0.0001** (specifically, the context notes a p-value of **0.001** for relapse in multivariate analysis).  \n- **P-value for overall survival**: **0.02** (also significant).  \nThis indicates that **HER-2/neu amplification independently predicts a higher risk of relapse and poorer survival** even after accounting for other prognostic factors (e.g., tumor size, nodal status). The extremely low p-values (<0.001) confirm strong statistical significance, highlighting HER-2/neu as a critical biomarker for prognosis and treatment stratification.",
    "ground_truth": "According to the multivariate analysis presented in the excerpt, HER-2/neu is a statistically significant prognostic factor for relapse in node-positive breast cancer patients. Specifically, the paper states that HER-2/neu has a p-value of '0.001 (0.1378 \u00b1 0.0425)' for relapse in the multivariate analysis. This demonstrates that HER-2/neu is a strong predictor of disease recurrence, with a highly significant p-value of 0.001.",
    "source": "her - 2 / neu 0. 0011 < 0. 0001 0. 02 ( 0. 0872 \u00b1 0. 0388 ) 0. 001 ( 0. 1378 \u00b1 0. 0425 )",
    "difficulty": "hard",
    "confidence": "medium",
    "timestamp": "2025-05-14 14:03:27",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 16.686705589294434
  },
  {
    "id": 13,
    "repeat_id": 2,
    "question": "What is the statistical significance of HER-2/neu as a prognostic factor for relapse in node-positive breast cancer patients according to the multivariate analysis?",
    "answer": "\nIn the **multivariate analysis** of the study, **HER-2/neu amplification** demonstrated **statistically significant** associations with **relapse** in node-positive breast cancer patients:  \n- **P-value for relapse**: **<0.0001** (specifically, the context notes a p-value of **0.001** for relapse in multivariate analysis).  \nThis extremely low p-value confirms that **HER-2/neu amplification is an independent prognostic factor** for increased relapse risk, even after adjusting for other variables (e.g., tumor size, nodal status). The significance underscores its role as a critical biomarker for stratifying patients and guiding targeted therapies.",
    "ground_truth": "According to the multivariate analysis presented in the excerpt, HER-2/neu is a statistically significant prognostic factor for relapse in node-positive breast cancer patients. Specifically, the paper states that HER-2/neu has a p-value of '0.001 (0.1378 \u00b1 0.0425)' for relapse in the multivariate analysis. This demonstrates that HER-2/neu is a strong predictor of disease recurrence, with a highly significant p-value of 0.001.",
    "source": "her - 2 / neu 0. 0011 < 0. 0001 0. 02 ( 0. 0872 \u00b1 0. 0388 ) 0. 001 ( 0. 1378 \u00b1 0. 0425 )",
    "difficulty": "hard",
    "confidence": "medium",
    "timestamp": "2025-05-14 14:03:35",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 8.539424896240234
  },
  {
    "id": 13,
    "repeat_id": 3,
    "question": "What is the statistical significance of HER-2/neu as a prognostic factor for relapse in node-positive breast cancer patients according to the multivariate analysis?",
    "answer": "\nIn the **multivariate analysis** of the study, **HER-2/neu amplification** showed **statistically significant** prognostic value for **relapse** in node-positive breast cancer patients:  \n- **P-value for relapse**: **0.001** (indicating strong statistical significance, as it is well below the conventional threshold of 0.05).  \nThis result confirms that **HER-2/neu status is an independent predictor of relapse risk** after accounting for other clinical variables (e.g., tumor size, nodal status). The low p-value highlights its critical role as a biomarker for prognosis and treatment stratification in this patient population.",
    "ground_truth": "According to the multivariate analysis presented in the excerpt, HER-2/neu is a statistically significant prognostic factor for relapse in node-positive breast cancer patients. Specifically, the paper states that HER-2/neu has a p-value of '0.001 (0.1378 \u00b1 0.0425)' for relapse in the multivariate analysis. This demonstrates that HER-2/neu is a strong predictor of disease recurrence, with a highly significant p-value of 0.001.",
    "source": "her - 2 / neu 0. 0011 < 0. 0001 0. 02 ( 0. 0872 \u00b1 0. 0388 ) 0. 001 ( 0. 1378 \u00b1 0. 0425 )",
    "difficulty": "hard",
    "confidence": "medium",
    "timestamp": "2025-05-14 14:03:44",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 9.04068112373352
  },
  {
    "id": 14,
    "repeat_id": 1,
    "question": "How does HER-2/neu gene amplification relate to patient prognosis in node-positive breast cancer cases?",
    "answer": "\nIn node-positive breast cancer, **HER-2/neu gene amplification** is strongly associated with **poorer prognosis**, as evidenced by the study's **multivariate analysis**:  \n1. **Relapse Risk**:  \n   - Patients with HER-2/neu amplification had a **significantly higher risk of relapse** (p = 0.001), indicating this biomarker is an independent predictor of disease recurrence.  \n2. **Overall Survival**:  \n   - HER-2/neu amplification was also linked to **reduced overall survival** (p = 0.02), further emphasizing its role as a negative prognostic factor.  \n3. **Clinical Implications**:  \n   - These findings highlight HER-2/neu status as a critical biomarker for **risk stratification** and potential targets for therapies (e.g., anti-HER-2 agents like trastuzumab).  \nThe statistical significance (p < 0.001 for relapse) underscores its robust association with adverse outcomes, even after adjusting for other clinical variables.",
    "ground_truth": "The excerpt indicates that amplification of the HER-2/neu gene is a strong prognostic factor in node-positive breast cancer patients. Specifically, it states: 'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients.' This demonstrates that HER-2/neu amplification is significant even when considering other prognostic factors.",
    "source": "'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients'",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 14:03:53",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 8.958548545837402
  },
  {
    "id": 14,
    "repeat_id": 2,
    "question": "How does HER-2/neu gene amplification relate to patient prognosis in node-positive breast cancer cases?",
    "answer": "\nIn node-positive breast cancer, **HER-2/neu gene amplification** is strongly associated with **adverse prognosis**, as demonstrated by the study's **multivariate analysis**:  \n- **Relapse Risk**: Patients with HER-2/neu amplification had a **significantly higher risk of relapse** (p = 0.001), indicating this biomarker is an independent predictor of disease recurrence.  \n- **Overall Survival**: HER-2/neu amplification was also linked to **reduced overall survival** (p = 0.02), further emphasizing its role as a negative prognostic factor.  \nThese findings highlight that HER-2/neu status is a critical biomarker for **risk stratification** and informs treatment decisions, such as the use of targeted therapies (e.g., anti-HER-2 agents). The statistical significance (p < 0.001 for relapse) underscores its robust association with poor outcomes, even after adjusting for other clinical variables.",
    "ground_truth": "The excerpt indicates that amplification of the HER-2/neu gene is a strong prognostic factor in node-positive breast cancer patients. Specifically, it states: 'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients.' This demonstrates that HER-2/neu amplification is significant even when considering other prognostic factors.",
    "source": "'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients'",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 14:04:01",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 7.819189786911011
  },
  {
    "id": 14,
    "repeat_id": 3,
    "question": "How does HER-2/neu gene amplification relate to patient prognosis in node-positive breast cancer cases?",
    "answer": "\nIn node-positive breast cancer, **HER-2/neu gene amplification** is strongly associated with **poorer patient outcomes**, as shown by the study's **multivariate analysis**:  \n- **Relapse Risk**: HER-2/neu amplification is independently linked to a **significantly higher risk of relapse** (p = 0.001), indicating a strong negative prognostic impact.  \n- **Overall Survival**: Patients with HER-2/neu amplification also experience **reduced overall survival** (p = 0.02), further solidifying its role as a marker of aggressive disease.  \nThese findings underscore the importance of HER-2/neu status in **risk stratification** and guide therapeutic strategies, such as anti-HER-2 targeted therapies. The statistical significance (p < 0.001 for relapse) confirms its robust association with adverse prognosis, even after accounting for other clinical factors.",
    "ground_truth": "The excerpt indicates that amplification of the HER-2/neu gene is a strong prognostic factor in node-positive breast cancer patients. Specifically, it states: 'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients.' This demonstrates that HER-2/neu amplification is significant even when considering other prognostic factors.",
    "source": "'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients'",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 14:04:09",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 8.26595687866211
  },
  {
    "id": 15,
    "repeat_id": 1,
    "question": "Based on the comparison of amplification levels for two related tyrosine kinase receptors in human breast cancer, what conclusion does the excerpt draw regarding the generality of gene amplification as a phenomenon in this specific malignancy?",
    "answer": "\nThe excerpt likely concludes that **gene amplification is not a general phenomenon** across all tyrosine kinase receptors in human breast cancer, but rather **specific to certain genes** (e.g., *HER-2/neu*). By comparing amplification levels of two related receptors, the study may demonstrate that while one receptor (e.g., *HER-2/neu*) is frequently amplified and associated with aggressive disease, the other receptor (e.g., *EGFR*) shows less or no amplification. This highlights the **context-specific nature of gene amplification** in breast cancer, emphasizing that it is a **selective event** rather than a universal mechanism. Such findings underscore the importance of receptor-specific amplification in driving oncogenic pathways and clinical outcomes.",
    "ground_truth": "The excerpt concludes that the significant difference in amplification levels between the two related tyrosine kinase receptors suggests that gene amplification is not a universally applicable phenomenon for this class of receptors in human breast cancer. Specifically, the paper states: \"of the former to be 14 times greater than that of the latter, indicating that the phenomenon of gene amplification is not a general one for a related tyrosine kinase - specific receptor in human breast cancer.\"",
    "source": "of the former to be 14 times greater than that of the latter, indicating that the phenomenon of gene amplification is not a general one for a related tyrosine kinase - specific receptor in human breast cancer.",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 14:04:21",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 11.954543828964233
  },
  {
    "id": 15,
    "repeat_id": 2,
    "question": "Based on the comparison of amplification levels for two related tyrosine kinase receptors in human breast cancer, what conclusion does the excerpt draw regarding the generality of gene amplification as a phenomenon in this specific malignancy?",
    "answer": "\nThe excerpt likely concludes that **gene amplification is not a general phenomenon** in human breast cancer but rather **specific to certain tyrosine kinase receptors**. By comparing amplification levels between two related receptors (e.g., *HER-2/neu* and another, such as *EGFR*), the study may demonstrate that amplification occurs selectively in one receptor (e.g., *HER-2/neu*) but not the other. This suggests that **gene amplification is a context-dependent event**, driven by the unique oncogenic roles of specific receptors in breast cancer. Thus, the conclusion emphasizes that while amplification is a significant mechanism in some cases, it is **not universally prevalent** across all tyrosine kinase receptors in this malignancy.",
    "ground_truth": "The excerpt concludes that the significant difference in amplification levels between the two related tyrosine kinase receptors suggests that gene amplification is not a universally applicable phenomenon for this class of receptors in human breast cancer. Specifically, the paper states: \"of the former to be 14 times greater than that of the latter, indicating that the phenomenon of gene amplification is not a general one for a related tyrosine kinase - specific receptor in human breast cancer.\"",
    "source": "of the former to be 14 times greater than that of the latter, indicating that the phenomenon of gene amplification is not a general one for a related tyrosine kinase - specific receptor in human breast cancer.",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 14:04:31",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 9.249494552612305
  },
  {
    "id": 15,
    "repeat_id": 3,
    "question": "Based on the comparison of amplification levels for two related tyrosine kinase receptors in human breast cancer, what conclusion does the excerpt draw regarding the generality of gene amplification as a phenomenon in this specific malignancy?",
    "answer": "\nThe excerpt concludes that **gene amplification is not a general phenomenon** in human breast cancer but is **specific to certain tyrosine kinase receptors**. By comparing amplification levels between two related receptors (e.g., *HER-2/neu* and another, such as *EGFR*), the study likely demonstrates that amplification occurs selectively in one receptor (e.g., *HER-2/neu*) but not the other. This highlights that **gene amplification is a context-specific event** in breast cancer, driven by the unique oncogenic roles of individual receptors, rather than a universal mechanism across all tyrosine kinase receptors.",
    "ground_truth": "The excerpt concludes that the significant difference in amplification levels between the two related tyrosine kinase receptors suggests that gene amplification is not a universally applicable phenomenon for this class of receptors in human breast cancer. Specifically, the paper states: \"of the former to be 14 times greater than that of the latter, indicating that the phenomenon of gene amplification is not a general one for a related tyrosine kinase - specific receptor in human breast cancer.\"",
    "source": "of the former to be 14 times greater than that of the latter, indicating that the phenomenon of gene amplification is not a general one for a related tyrosine kinase - specific receptor in human breast cancer.",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 14:04:38",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 7.465839147567749
  },
  {
    "id": 16,
    "repeat_id": 1,
    "question": "What statistical method was used to evaluate the predictive power of prognostic factors in the study?",
    "answer": "\nThe study likely used **Cox proportional hazards regression analysis** to evaluate the predictive power of prognostic factors. This method is standard in survival analysis and allows researchers to assess the association between variables (e.g., HER-2/neu amplification, tumor size, grade) and time-to-event outcomes (e.g., relapse, mortality) while adjusting for confounding factors. \nKey aspects of this approach include:\n- **Hazard ratios (HRs)** to quantify the risk of an event (e.g., relapse) associated with each factor.\n- **P-values** to test the statistical significance of each factor's predictive power (e.g., *p* = 0.001 for relapse, *p* = 0.02 for overall survival, as previously mentioned).\n- **Multivariable analysis** to account for interactions and confounding variables, ensuring that the observed associations are independent predictors.\nThis method provides robust evidence for the role of specific factors in prognosis by modeling their impact on survival outcomes over time.",
    "ground_truth": "The study utilized Cox's partial nonparametric regression model to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner. Specifically, the paper states: 'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.' This demonstrates that the researchers aimed to analyze multiple factors simultaneously to understand their impact on patient outcomes.",
    "source": "'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.'",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 14:04:49",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 10.625729322433472
  },
  {
    "id": 16,
    "repeat_id": 2,
    "question": "What statistical method was used to evaluate the predictive power of prognostic factors in the study?",
    "answer": "\nThe study used **Cox proportional hazards regression analysis** to evaluate the predictive power of prognostic factors. This method is standard for analyzing survival data and assesses the relationship between variables (e.g., HER-2/neu status, tumor size, grade) and time-to-event outcomes (e.g., relapse-free survival, overall survival). Key features of this approach include:\n1. **Hazard Ratios (HRs):** Quantify the risk of an event (e.g., relapse or death) associated with each prognostic factor, adjusted for other variables.\n2. **P-values:** Test the statistical significance of each factor's predictive power (e.g., *p* = 0.001 for relapse, *p* = 0.02 for overall survival).\n3. **Multivariable Analysis:** Accounts for confounding variables, ensuring that the observed associations are independent predictors of outcome.\nThis method provides robust evidence for the role of specific factors in prognosis by modeling their impact on survival outcomes over time.",
    "ground_truth": "The study utilized Cox's partial nonparametric regression model to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner. Specifically, the paper states: 'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.' This demonstrates that the researchers aimed to analyze multiple factors simultaneously to understand their impact on patient outcomes.",
    "source": "'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.'",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 14:04:59",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 9.950241088867188
  },
  {
    "id": 16,
    "repeat_id": 3,
    "question": "What statistical method was used to evaluate the predictive power of prognostic factors in the study?",
    "answer": "\nThe study used **Cox proportional hazards regression analysis** to evaluate the predictive power of prognostic factors. This method is standard for analyzing survival data and assesses the relationship between variables (e.g., HER-2/neu status, tumor size, grade) and time-to-event outcomes (e.g., relapse-free survival, overall survival). Key features of this approach include:\n1. **Hazard Ratios (HRs):** Quantify the risk of an event (e.g., relapse or death) associated with each prognostic factor, adjusted for other variables.\n2. **P-values:** Test the statistical significance of each factor's predictive power (e.g., *p* = 0.001 for relapse, *p* = 0.02 for overall survival).\n3. **Multivariable Analysis:** Accounts for confounding variables, ensuring that the observed associations are independent predictors of outcome.\nThis method provides robust evidence for the role of specific factors in prognosis by modeling their impact on survival outcomes over time.",
    "ground_truth": "The study utilized Cox's partial nonparametric regression model to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner. Specifically, the paper states: 'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.' This demonstrates that the researchers aimed to analyze multiple factors simultaneously to understand their impact on patient outcomes.",
    "source": "'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.'",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 14:05:08",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 9.772201538085938
  },
  {
    "id": 17,
    "repeat_id": 1,
    "question": "Based on the structural description provided in the excerpt for the protein identified as \"[Chunk 8]\", what specific features lead to the inference that it is likely a cellular receptor?",
    "answer": "\nThe inference that the protein in \"[Chunk 8]\" is a cellular receptor likely stems from specific structural features commonly associated with receptors, such as:\n1. **Extracellular Ligand-Binding Domain:**  \n   The presence of a region capable of interacting with extracellular signaling molecules (e.g., growth factors, hormones) suggests a role in receptor-mediated signal transduction.\n2. **Transmembrane Domain:**  \n   A hydrophobic transmembrane segment (e.g., a single \u03b1-helix) anchors the protein in the cell membrane, a hallmark of membrane-bound receptors.\n3. **Intracellular Signaling Domain:**  \n   A cytoplasmic region containing motifs like tyrosine kinase domains (if it is a receptor tyrosine kinase) or other signaling modules (e.g., SH2, SH3 domains) indicates downstream signaling capabilities.\n4. **Conserved Motifs or Structural Domains:**  \n   Specific structural elements, such as the immunoglobulin (Ig)-like fold in some receptors or the fibronectin type III (FNIII) domain, may be described in the chunk, further supporting its classification as a receptor.\n5. **Dimerization Interface:**  \n   Evidence of a dimerization site or interface (e.g., through disulfide bonds or hydrophobic interactions) would align with the functional requirement of many receptors to dimerize upon ligand binding.\nThese features collectively support the conclusion that the protein is a cellular receptor, as they align with the structural and functional characteristics of such proteins. If the chunk explicitly mentions any of these elements, they would directly underpin the inference.",
    "ground_truth": "According to the excerpt, the inference that the protein \"[Chunk 8]\" is likely a cellular receptor is based on its specific domain structure. The text states: \"[Chunk 8] has an extracellular domain, a transmembrane domain that includes two cysteine - rich repeat clusters, and an intracellular kinase domain, indicating that it too is likely to be a cellular receptor for an as yet unidentified ligand.\" These distinct domains, particularly the extracellular and transmembrane components, are characteristic of receptor proteins.",
    "source": "[Chunk 8] has an extracellular domain, a transmembrane domain that includes two cysteine - rich repeat clusters, and an intracellular kinase domain, indicating that it too is likely to be a cellular receptor for an as yet unidentified ligand.",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 14:05:22",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 13.818458557128906
  },
  {
    "id": 17,
    "repeat_id": 2,
    "question": "Based on the structural description provided in the excerpt for the protein identified as \"[Chunk 8]\", what specific features lead to the inference that it is likely a cellular receptor?",
    "answer": "\nThe inference that the protein in \"[Chunk 8]\" is a cellular receptor is supported by specific structural features typically associated with receptors, such as:\n1. **Extracellular Ligand-Binding Domain:**  \n   The presence of a region capable of interacting with extracellular signaling molecules (e.g., growth factors, hormones) suggests a role in receptor-mediated signal transduction.\n2. **Transmembrane Domain:**  \n   A hydrophobic transmembrane segment (e.g., a single \u03b1-helix) anchors the protein in the cell membrane, a hallmark of membrane-bound receptors.\n3. **Intracellular Signaling Domain:**  \n   A cytoplasmic region containing motifs like tyrosine kinase domains (if it is a receptor tyrosine kinase) or other signaling modules (e.g., SH2, SH3 domains) indicates downstream signaling capabilities.\n4. **Conserved Motifs or Structural Domains:**  \n   Specific structural elements, such as the immunoglobulin (Ig)-like fold in some receptors or the fibronectin type III (FNIII) domain, may be described in the chunk, further supporting its classification as a receptor.\n5. **Dimerization Interface:**  \n   Evidence of a dimerization site or interface (e.g., through disulfide bonds or hydrophobic interactions) would align with the functional requirement of many receptors to dimerize upon ligand binding.\nThese features collectively support the conclusion that the protein is a cellular receptor, as they align with the structural and functional characteristics of such proteins. If the chunk explicitly mentions any of these elements, they would directly underpin the inference.",
    "ground_truth": "According to the excerpt, the inference that the protein \"[Chunk 8]\" is likely a cellular receptor is based on its specific domain structure. The text states: \"[Chunk 8] has an extracellular domain, a transmembrane domain that includes two cysteine - rich repeat clusters, and an intracellular kinase domain, indicating that it too is likely to be a cellular receptor for an as yet unidentified ligand.\" These distinct domains, particularly the extracellular and transmembrane components, are characteristic of receptor proteins.",
    "source": "[Chunk 8] has an extracellular domain, a transmembrane domain that includes two cysteine - rich repeat clusters, and an intracellular kinase domain, indicating that it too is likely to be a cellular receptor for an as yet unidentified ligand.",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 14:05:30",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 8.111209154129028
  },
  {
    "id": 17,
    "repeat_id": 3,
    "question": "Based on the structural description provided in the excerpt for the protein identified as \"[Chunk 8]\", what specific features lead to the inference that it is likely a cellular receptor?",
    "answer": "\nThe inference that the protein in \"[Chunk 8]\" is a cellular receptor is based on structural features such as:\n1. **Extracellular Ligand-Binding Domain:**  \n   The presence of a region with structural motifs (e.g., immunoglobulin-like folds, fibronectin type III domains) that suggest interaction with extracellular ligands (e.g., growth factors, hormones).\n2. **Transmembrane Segment:**  \n   A hydrophobic \u03b1-helical region that spans the cell membrane, anchoring the protein in the plasma membrane and enabling signal transduction across the membrane.\n3. **Intracellular Signaling Domain:**  \n   A cytoplasmic region containing tyrosine kinase domains or other signaling modules (e.g., SH2, SH3 domains) that mediate downstream signaling upon receptor activation.\n4. **Dimerization Interface:**  \n   Structural evidence of a dimerization site (e.g., through disulfide bonds, hydrophobic interactions, or hydrogen bonding) that facilitates receptor dimerization, a common mechanism for signal amplification.\n5. **Conserved Structural Domains:**  \n   Presence of conserved domains (e.g., kinase domains, cysteine-rich regions) that are characteristic of receptor families (e.g., receptor tyrosine kinases, G-protein-coupled receptors).\nThese features collectively align with the structural and functional hallmarks of cellular receptors, supporting the classification. If the chunk explicitly describes any of these elements, they would directly underpin the inference.",
    "ground_truth": "According to the excerpt, the inference that the protein \"[Chunk 8]\" is likely a cellular receptor is based on its specific domain structure. The text states: \"[Chunk 8] has an extracellular domain, a transmembrane domain that includes two cysteine - rich repeat clusters, and an intracellular kinase domain, indicating that it too is likely to be a cellular receptor for an as yet unidentified ligand.\" These distinct domains, particularly the extracellular and transmembrane components, are characteristic of receptor proteins.",
    "source": "[Chunk 8] has an extracellular domain, a transmembrane domain that includes two cysteine - rich repeat clusters, and an intracellular kinase domain, indicating that it too is likely to be a cellular receptor for an as yet unidentified ligand.",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 14:05:42",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 12.027377605438232
  },
  {
    "id": 18,
    "repeat_id": 1,
    "question": "What statistical method was used to evaluate the predictive power of prognostic factors in the study?",
    "answer": "\nThe current context does not provide specific information about a study or the statistical methods used to evaluate prognostic factors. To address this query accurately, please clarify which study or dataset you are referring to, or provide additional details about the analysis. If the knowledge base contains relevant information, I can retrieve it for you.",
    "ground_truth": "The study utilized Cox's partial nonparametric regression model to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner. Specifically, the paper states: 'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.' This demonstrates that the researchers aimed to analyze multiple factors simultaneously to understand their impact on patient outcomes.",
    "source": "'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.'",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 14:05:49",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 7.066499710083008
  },
  {
    "id": 18,
    "repeat_id": 2,
    "question": "What statistical method was used to evaluate the predictive power of prognostic factors in the study?",
    "answer": "\nThe current context does not include specific information about a study or the statistical methods used to evaluate prognostic factors. To provide an accurate answer, please specify the study, dataset, or context you are referring to. If the knowledge base contains relevant details, I can retrieve them for you.",
    "ground_truth": "The study utilized Cox's partial nonparametric regression model to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner. Specifically, the paper states: 'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.' This demonstrates that the researchers aimed to analyze multiple factors simultaneously to understand their impact on patient outcomes.",
    "source": "'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.'",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 14:05:52",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.2717196941375732
  },
  {
    "id": 18,
    "repeat_id": 3,
    "question": "What statistical method was used to evaluate the predictive power of prognostic factors in the study?",
    "answer": "\nThe current context does not include specific information about a study or the statistical methods used to evaluate prognostic factors. To provide an accurate answer, please specify the study, dataset, or context you are referring to. If the knowledge base contains relevant details, I can retrieve them for you.",
    "ground_truth": "The study utilized Cox's partial nonparametric regression model to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner. Specifically, the paper states: 'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.' This demonstrates that the researchers aimed to analyze multiple factors simultaneously to understand their impact on patient outcomes.",
    "source": "'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.'",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 14:05:53",
    "model_name": "qwen3:8b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 1.4259967803955078
  }
]